COVID-19 has affected the rating of a number of end of life options. (Yellow in the RPA chart below).
Specifically, chloroquine is now much less accessible. Nembutal as an over-the-counter purchase is out, but this is compensated to some extent, by the easier mail-order environment for some restricted substances. The availability of the R2D DeBreather has been interrupted while and the Sarco project is also delayed. The Swiss option remains seriously affected by travel restrictions.